Screening for REEP1 Mutations in 31 Chinese Hereditary Spastic Paraplegia Families

Xinran Ma 1†, Ji He 1†, Xiaoxuan Liu 1 and Dongsheng Fan 1,2,3*

1 Department of Neurology, Peking University Third Hospital, Beijing, China, 2 Beijing Municipal Key Laboratory of Biomarker and Translational Research in Neurodegenerative Diseases, Beijing, China, 3 Key Laboratory for Neuroscience, National Health Commission/Ministry of Education, Peking University, Beijing, China

**Background:** REEP1 is a common cause of autosomal dominant hereditary spastic paraplegia (HSP) but is rare in China. The pathological mechanism of REEP1 is not fully understood.

**Methods:** We screened for REEP1 mutations in 31 unrelated probands from Chinese HSP families using next-generation sequencing targeting pathogenic genes for HSP and other related diseases. All variants were validated by Sanger sequencing. The proband family members were also screened for variants for the segregation analysis. All previously reported REEP1 mutations and cases were reviewed to clarify the genetic and clinical features of REEP1-related HSP.

**Results:** A pathogenic mutation, REEP1c. 125G>A (p.Trp42*), was detected in a pure HSP family from North China out of 31 HSP families (1/31). This locus, which is located in the second hydrophobic domain of REEP1, is detected in both Caucasian patients with complicated HSP phenotypes and Chinese pure HSP families.

**Conclusion:** REEP1-related HSP can be found in the Chinese population. The 42nd residue is a novel transethnic mutation hotspot. Mutations in this spot can lead to both complicated and pure form of HSP. Identification of tranethnic hotspot will contribute to clarify the underlying pathological mechanisms.

**Keywords:** hereditary spastic paraplegia, receptor expression-enhancing protein 1, mutation analysis, transethnic, hotspot

**INTRODUCTION**

Hereditary spastic paraplegia (HSP) comprises a group of neurodegenerative diseases characterized by spastic paraplegia of the lower limbs (1). Hereditary spastic paraplegia is classified as pure or complicated HSP based on whether impairment is restricted to the pyramidal system (2). Approximately 79 pathogenic genes for HSPs have been found (3). These diseases can be inherited in various ways, including autosomal dominant (AD), recessive, X-linked, mitochondrial, and other mechanisms (4). The only treatment to date for HSP is symptomatic treatment. Because HSPs are monogenic diseases, gene therapies, and precision medicine may be appropriate (3).

Loss-of-function mutations of REEP1 (receptor expression enhancing protein 1), a mediator of endoplasmic reticulum (ER)–mitochondrial interactions, can lead to AD HSP (5–7). In a previous study of HSP cohorts, REEP1 mutations were found to be rare in the Chinese population (8).
Here, we screened for REEP1 mutations using next-generation sequencing (NGS) in 31 Chinese HSP families and performed a general review of REEP1-related HSP, which helped to elucidate the genetic and clinical features of this disease.

METHODS

Subjects
From January 2012 to September 2019, 31 Chinese families clinically diagnosed with HSP according to Harding’s criteria (2) in Peking University Third Hospital were enrolled in this study. All the probands and their relatives received detailed clinical examinations. All participants provided written informed consent. The study was approved by the Peking University Third Hospital ethics committee.

Genetic Test and Mutation Analysis
Peripheral blood was obtained from all the participants, and DNA was isolated. Next-generation sequencing targeting ∼160 genes related to Charcot-Marie-Tooth disease, HSP, and amyotrophic lateral sclerosis, including REEP1_NM_022912.2, was conducted (the gene list and detailed sequencing and mutation analysis procedure are shown in Supplementary File and Supplementary Table 1). All identified variants were validated by Sanger sequencing. The relatives of the probands were also screened for these variants via Sanger sequencing for the segregation analysis. The detailed Sanger sequencing procedure for the identified REEP1 variants is shown in Supplementary Table 2.

RESULTS

Eighteen unrelated HSP probands and their relatives from mainland China were recruited for the study (Table 1). Twenty-one probands were male, and 10 were female. The average age at onset was 33.8 ± 13.3 years. Ten families presented with a complicated phenotype. The accompanying symptoms included neuropathy (5/10), extrapyramidal impairments (parkinsonism 1/10, dystonia 1/10), white matter lesions (1/10), dysphagia (1/10), deafness (1/10), nystagmus (1/10), and cognitive impairment (1/10).

Genetic Results
Genetic variants in pathogenic genes of HSP were identified in eight probands, with a diagnostic rate of 25.8%. Three of them were known causative mutations for HSP (Table 2) (9–11). Two known pathogenic mutations and a novel mutation of SPAST were detected in three probands (9.7%). The possible damaging variants were listed in Supplementary Table 3, including KIAA0196 (1/31), AP5Z1 (1/31), DDHD1 (1/31), and SPG7 (1/31). A previously reported (9) pathogenic non-sense mutation of REEP1 c.125G>A (p.Trp42*) (RefSeq NM_022912) in exon 3 was detected in a pure HSP proband via NGS and then validated by Sanger sequencing (Figure 1).

This mutation was detected in all affected members but not the unaffected ones via Sanger sequencing, which is consistent with an AD model of inheritance. Moreover, the mutation was not found in population databases such as ExAC and 1,000 Genomes. Obvious cosegregation was found in the examined family. Next-generation sequencing showed no pathogenic or likely pathogenic mutations in other causative genes of spastic paraplegia such as SPAST and so on. The phenotype of these individuals was also consistent with a previous case. Therefore, we concluded that REEP1 c.125G>A (p.Trp42*) is a pathogenic mutation in this family.

Clinical Manifestation of the HSP Family
With REEP1 Mutation
All the cases in the family from North China with the mutation were consistent with pure HSP (Figure 1B). The proband (III-4) was a 51-year-old woman who complained of walking difficulty and lower limb stiffness starting at ∼20 years of age. Recently, she had also experienced urgency of urination without urinary incontinence. Her symptoms progressed slowly during subsequent years. Her family members (I-1, II-1, III-3, III-5, and III-6) had similar symptoms that were limited to lower limb stiffness and urgency of urination. They all received detailed clinical examinations. Other systems were normal. The age at onset for III-3, III-4, III-5, and III-6 ranged from 10 to 30 years. Patient III-6 died of a traffic accident when he was 31 years old.

DISCUSSION

In this study, genetic variants in HSP genes were detected in eight probands. The frequencies of rare HSP genes in our study are similar to those in a previous study (12). Although SPAST was the most common cause for ADHSP (12), accounting for ∼50% of ADHSP families in China (13), known pathogenic SPAST mutations were detected in only two probands in our cohort (the detailed information are shown in Supplementary File). That may be due to different sequencing methods and small sample size. (We used NGS-based method to detect copy number variation in Supplementary File). Our study may indicate the advantages and disadvantages of NGS. Other sequencing methods could not be substituted.
A known pathogenic mutation, p.W42∗, in the second hydrophobic domain (HD) of REEP1, was detected, which was previously detected in a pure HSP patient in Norway (9). W42R is a missense mutation in the same amino acid that was found to cause complicated HSP with neuropathy in French Caucasians (14). Both non-sense and missense mutations at the W42 locus have been found to be pathogenic in different ethnicities, indicating that this locus is a transethnic hotspot that plays an important role in the pathogenesis of HSP. Mutations in this locus can lead to both pure and complicated phenotypes, indicating substantial heterogeneity of this transethnic hotspot.
**FIGURE 2** | Illustration of the REEP1 protein. REEP1 contains 2 hydrophobic domains and a conserved TB2/DP1/HVA22 domain. There is also a miRNA target region in the 3′ UTR of REEP1 mRNA. All reported pathogenic mutations of REEP1 are shown except for 2p11.2-2p12 deletions. HD, hydrophobic domain.

**TABLE 3** | REEP1 mutation rate in different regions.

| Region            | Result                                                                 | Reference |
|-------------------|------------------------------------------------------------------------|-----------|
| China             | 0/120 (54 ADHSP families and 66 sporadic cases)                        | (13)      |
|                   | 1/31 (31 HSP families)                                                 | Our study |
| Germany           | 4.3% ADHSP (162 pure HSP families)                                      | (28)      |
| The United Kingdom| 2.3% ADHSP (133 families and 80 cases)                                  | (27)      |
| The Netherlands   | 7.4% in SPAST negative AD HSP (27 families and 110 cases)              | (28)      |
| Europe            | 6.5% all HSP (80 families)                                             | (7)       |
| France            | 4.5% ADHSP (175 families)                                              | (14)      |
| North America     | 5.0% all HSP (120 patients)                                            | (29)      |
| Poland            | 3.2% all HSP (85 families and 131 cases)                               | (31)      |
| Korea             | 0/27 (27 patients)                                                     | (38)      |
| Japan             | 4.1% ADHSP (66 families and 63 cases)                                  | (24)      |

ADHSP, autosomal dominant hereditary spastic paraplegia; SPAST, spastin.

REEP1 is a causative gene of HSP and distal hereditary motor neuropathy type 5B (15), and REEP1-related diseases also include 2p11.2-2p12 deletion syndrome (16). The extension of the REEP1 protein and mislocalized REEP1 can lead to “toxic gain of function” and result in dHMN (15, 17), whereas loss of function may lead to HSP (5–7).

The REEP1 protein is located in the mitochondria and ER and participates in the functional activities of organelles, such as the interaction between the tubular ER and microtubules and peripheral ER shaping (5–7). To date, ~60 pathogenic mutations of REEP1 have been reported, including missense mutations, non-sense mutations, exon deletions, splicing site mutations, and miRNA binding site mutations (Figure 2). The REEP1 protein has a conserved TB2/DP1/HVA22 domain that may have a chaperone-like function (7, 18). Additionally, it contains a mitochondria-localization domain (6) (between aa116 and aa157 in NP_075063.1) and a cytoplasmic C-terminus that is in contact with microtubules (19). There is also a highly conserved miRNA binding site in the 3′ UTR of REEP1 mRNA, and pathogenic mutations in this region influence its post-transcriptional regulation (20). Many missense mutations of REEP1 are located near the N terminus (20, 21), indicating that it is a hotspot region. Mutations in the N terminus (before the 55th amino acid) influence the localization of REEP1 in the ER (21). This region contains two HDs, HD1 in the N terminus, and HD2 near the middle, which is located in the conserved domain. HD2
forms a hairpin-like structure to interact with SPAST and ALT1 in the ER (19, 21). Their interactions mediate ER shaping and are very important for the ER network between the cell body and axon in motor neurons (22). Disruption of the hairpin domain harms the ER organization in distal axons, which may explain the length-dependent degeneration of upper motor neurons in HSP (22). The novel transethnic hotspot W42 is located in the hairpin domain. Thus, it can disturb the normal function of this domain and lead to pathogenesis.

More than 70 REEP1-related HSP pedigrees have been reported (7, 9, 14, 15, 17, 20, 23–35), and their genotypes and phenotypes are summarized in Supplementary Table 4. There is generally an early age at onset, commonly 0–20 and 30–35 years of age (14). The mutation of REEP1 typically results in AD pure HSP but can cause complicated HSP. The accompanying symptoms include neuropathy (23), tremor, and cognitive impairment (14). Few mutations can lead to both complicated and pure HSP phenotypes. The clinical manifestations can also vary among different ethnicities.

The mutation rate of REEP1 in HSP varies in different regions (7, 13, 14, 24, 26–29, 31, 36) (Table 3). Although REEP1 was reported to be the third most common cause of HSP in some countries (20), previous screening studies in Chinese patients did not find pathogenic REEP1 variants (8, 13). In the present study, we found one family with pathogenic REEP1 mutation out of 31 HSP families, which is uncommon.

### CONCLUSION

REEP1-related HSP can be found in the Chinese population. The 42nd residue is a novel transethnic mutation hotspot. Mutations in this spot can lead to both complicated and pure form of HSP. Identification of transethnic hotspot will contribute to clarify the underlying pathological mechanisms.

### DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

### ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Peking University Third Hospital Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

### AUTHOR CONTRIBUTIONS

DF conceived this study and provide financial support. XM and JH performed the experiments, analyzed the data, and wrote the manuscript. XL provided supplementary data.

### FUNDING

This work was funded by the National Natural Science Foundation of China (81601105, 81471184, 81974197).

### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.00499/full#supplementary-material

### REFERENCES

1. Harding AE. Hereditary spastic paraplegias. *Semin Neurol*. (1993) 13:333–6. doi: 10.1055/s-2008-1041143
2. Harding AE. Classification of the hereditary ataxias and paraplegias. *Lancet*. (1983) 1:1151–5. doi: 10.1016/S0140-6736(83)92879-9
3. Shribman S, Reid E, Crosby AH, Houlden H, Warner TT. Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. *Lancet Neurol*. (2019) 18:1136–46. doi: 10.1016/S1474-4422(19)30235-2
4. Finsterer J, Loscher W, Quasthoff S, Wanschitz J, Auer-Grumbach M, Stevanin G. Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. *J Neurol Sci*. (2012) 318:1–18. doi: 10.1016/j.jns.2012.03.025
5. Beetz C, Koch N, Khundadze M, Zimmer G, Nietzsche S, Hertel N, et al. A spastic paraplegia mouse model reveals REEP1-dependent ER shaping. *J Clin Invest*. (2013) 123:4273–82. doi: 10.1172/JCI65665
6. Lim Y, Cho IT, Schoel LJ, Cho G, Golden JA. Hereditary spastic paraplegia-linked REEP1 modulates endoplasmic reticulum/mitochondria contacts. *Ann Neurol*. (2015) 78:679–96. doi: 10.1002/ana.24488
7. Zuchner S, Wang G, Tran-Viet KN, Nance MA, Gaskell PC, Vance JM, et al. Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. *Am J Hum Genet*. (2006) 79:365–9. doi: 10.1086/505361
8. Du J, Shen L, Zhao GH, Wang YG, Liao SS, Chen C, et al. Receptor expression-enhancing protein 1 gene (SPG31) mutations are rare in Chinese Han patients with hereditary spastic paraplegia. *Chin Med J*. (2009) 122:2064–6. doi: 10.3760/cma.j.issn.0366-6999.2009.17.019
9. Iqbal Z, Rydning SL, Wedding IM, Koht J, Pihlstrom L, Rengmark AH, et al. Targeted high throughput sequencing in hereditary ataxia and spastic paraplegia. *PLoS ONE*. (2017) 12:e0174667. doi: 10.1371/journal.pone.0174667
10. Shoukier M, Neesen J, Sauter SM, Argyriou L, Doerwald N, Pantakani DV, et al. Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia. *Eur J Hum Genet*. (2009) 17:187–94. doi: 10.1038/ejhg.2008.147
11. Svenstrup K, Bross P, Koeboed P, Hjermind LE, Ebberg H, Born AP, et al. Sequence variants in SPAST, SPG3A and HSPD1 in hereditary spastic paraplegia. *J Neurol*. (2009) 256:490–5. doi: 10.1007/s00415-009-0424
12. Dong EL, Wang C, Wu S, Lu YQ, Lin XH, Su HZ, et al. Clinical spectrum and genetic landscape for hereditary spastic paraplegias in China. *Mol Neurodegener*. (2018) 13:36. doi: 10.1186/s13024-018-0269-1
13. Luo Y, Chen C, Zhan Z, Wang Y, Du J, Hu Z, et al. Mutation and clinical characteristics of autosomal-dominant hereditary spastic paraplegias in China. *Neurodegener Dis*. (2014) 14:176–83. doi: 10.1159/000365513
14. Goizet C, Depienne C, Benard G, Boukhris A, Mundwiller E, Sole G, et al. REEP1 mutations in SPG31: frequency, mutational spectrum, and potential
association with mitochondrial morpho-functional dysfunction. *Hum Mutat.* (2011) 32:1118–27. doi: 10.1002/humu.21542

15. Beetz C, Pieber TR, Hertel N, Schabhuttl M, Fischer C, Trajanoski S, et al. Exome sequencing identifies a *REEP1* mutation involved in distal hereditary motor neuropathy type V. *Am J Hum Genet.* (2012) 91:139–45. doi: 10.1016/j.ajhg.2012.05.007

16. Stevens SJ, Blom EW, Sieweke MJ, Smeets EE, et al. A recurrent deletion syndrome at chromosome bands 2p11.2–2p12 flanked by segmental duplications at the breakpoints and including *REEP1*. *Eur J Hum Genet.* (2015) 23:543–6. doi: 10.1038/ejhg.2014.124

17. Bock AS, Gunther S, Mohr J, Goldberg LV, Jahic A, Klisch C, et al. A nonstop variant in *REEP1* causes peripheral neuropathy by unmasking a 3′UTR-encoded, aggregation-inducing motif. *Hum Mutat.* (2018) 39:193–6. doi: 10.1002/humu.23369

18. Chen CN, Chu CC, Zentella R, Pan SM, Ho TH. *AtHV A22* gene family in Arabidopsis: phylogenetic relationship, ABA and stress regulation, and tissue-specific expression. *Plant Mol Biol.* (2002) 49:633–44. doi: 10.1023/A:1015593715144

19. Park SH, Zhu PP, Parker RL, Blackstone C. Hereditary spastic paraplegia: novel mutations in the *REEP1* gene (SPG31). *Synapse* (2015) 79:523–30. doi: 10.1111/j.1468-1331.2010.03102.x

20. Beetz C, Schule R, Deconinck T, Tran-Viet KN, Zhu H, Kremer BP, et al. Functional mutation analysis provides evidence for a role of *REEP1* in lipid droplet biology. *Hum Mutat.* (2014) 35:497–504. doi: 10.1002/humu.22521

21. Falk J, Rohde M, Bekhite MM, Neugebauer S, Hemmerich P, Kiehn tof M, et al. Spastic paraplegia type 31: a novel *REEP1* splice site donor variant and expansion of the phenotype variability. *Parkinsonism Relat Disord.* (2018) 46:79–83. doi: 10.1016/j.parkreldis.2017.10.012

22. Yalcin B, Zhao L, Stofanko M, O'Sullivan NC, Kang ZH, Roost A, et al. Mutational analysis of *REEP1* in sporadic upper motor neuron syndromes. *J Neurol* (2013) 260:869–75. doi: 10.1007/s00415-012-6723-z

23. Toft A, Birk S, Ballegaard M, Duno M, Hjermind LE, Nielsen JE, et al. Mutation screening of spastin, atlastin, and *REEP1* in hereditary spastic paraplegia. *Clin Genet.* (2011) 79:523–30. doi: 10.1111/j.1399-0004.2011.01501.x

24. Ishiura H, Takahashi Y, Hayashi T, Saito K, Furuya H, Watanabe M, et al. Peripheral neuropathy in hereditary spastic paraplegia caused by *REEP1* variants. *Hum Mutat.* (2008) 29:1019–6. doi: 10.1002/humu.20402

25. Elert-Dobkowska E, Stepniak I, Krysa W, Rajkiewicz M, Rakowicz M, Sobanska A, et al. Molecular spectrum of the *SPAST, ATL1* and *REEP1* genes associated with pure hereditary spastic paraplegia. *Eur J Neurol.* (2011) 18:150–7. doi: 10.1111/j.1468-1331.2010.03102.x

26. Battini R, Fogli A, Borghetti D, Michelucci A, Peranza S, Baldinotti F, et al. Clinical and genetic findings in a series of Italian children with pure hereditary spastic paraplegia. *Eur J Neurol.* (2011) 18:150–7. doi: 10.1111/j.1468-1331.2010.03102.x

27. Kim TH, Lee JH, Park YE, Shin JH, Nam TS, Kim HS, et al. Mutation analysis of *SPAST, ATL1* and *REEP1* in Korean Patients with Hereditary Spastic Paraplegia. *J Clin Neurol.* (2014) 10:257–61. doi: 10.3988/jcn.2014.10.3.257

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Ma, He, Liu and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.